Clinical trials: Primary Glaucoma
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension…
- Trial name
- NCT04620135
- Testing
- Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Where
- Japan
- Volunteers
- 245 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-angle, Ocular Hypertension
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and…
- Trial name
- NCT03293992
- Testing
- 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Primary Open Angle Glaucoma, Healthy Subjects
Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor
The objectives of this study are to assess the safety and effectiveness of the SENSIMED Triggerfish® (TF) device in continuous recording of relative fluctuation in intraocular pressure (IOP).
- Trial name
- NCT01390779
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sensimed AG
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00864578
- Where
- Italy
- Sponsor
- Sooft Italia
Ocular Surface Disease, Primary Open Angle Glaucoma
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment…
- Trial name
- NCT04828057
- Testing
- Tafluprost, timolol maleate
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
Primary Open Angle Glaucoma
Effect of Xen Implantation on the Aqueous Humor Proteome
The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma.
- Trial name
- NCT04141865
- Testing
- Xen, Aqueous shunt
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Price Vision Group
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
The primary objective of this study was to compare the change in intraocular pressure (IOP) of three different doses of latanoprost (75, 100 and 125 ug/ml) to that of the marketed 50 ug/ml dose, in a dose ranging study.
- Trial name
- NCT01379144
- Testing
- latanoprost 75 ug, latanoprost 100 ug, latanoprost 125 ug
- Where
- 25 sites in Australia, Czechia and 6 more
- Volunteers
- 282 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-angle Glaucoma, Ocular Hypertension
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an…
- Trial name
- NCT00759239
- Testing
- Travoprost 0.004% / Timolol maleate 0.5%
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma
GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma
Glaucoma is a chronic and progressive optic neuropathy characterized by degeneration of ganglion cells and axons with loss of visual function.
- Trial name
- GlaucoT (NCT05253534)
- Testing
- GlaucoT Glaucoma Treatment Device
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Glaucot Teknoloji Anonim Sirketi
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants
The objective of this study was to evaluate the AqueSys XEN Implant [XEN® Gel Stent (XEN45 Implant)] for the treatment of moderate primary open angle glaucoma (POAG) participants when medications have failed to control…
- Trial name
- NCT02006693
- Testing
- XEN® Gel Stent, Cataract Surgery
- Where
- 21 sites in Austria, Belgium and 7 more
- Volunteers
- 199 people
- Sponsor
- AqueSys, Inc.
Glaucoma, Open-Angle, Normal Tension Glaucoma
Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)
The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who…
- Trial name
- NCT02863705
- Testing
- brimonidine tartrate/timolol malate Ophthalmic Solution, bimatoprost ophthalmic solution 0.01%
- Where
- 9 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Primary Open Angle Glaucoma
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to…
- Trial name
- CATALYST (NCT05564091)
- Testing
- Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
- Where
- 4 sites in United States, Germany
- Volunteers
- 78 people
- Sponsor
- Nova Eye, Inc.
Cataract, Glaucoma
Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study
The objective of this study is to determine the safety and effectiveness of the OculusGen™ (ologen) Biodegradable Collagen Matrix Implant in hacotrabeculectomy surgery.
- Trial name
- NCT00687791
- Testing
- ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Pro Top & Mediking Company Limited